Healthcare Innovation

A Michigan ear clinic's new partnership reveals a seismic shift in healthcare. Private equity and MSOs promise growth, but what does this mean for doctors?

With an oversubscribed $7.2M Series A, Icarus Medical is leveraging 3D printing and novel biomechanics to redefine treatment for millions with knee pain.

With the US approval of a modern UV filter, Inolex's LexFeel® Enhance MB is poised to finally give consumers sunscreens that are both highly effective and elegant.

Bristol Myers Squibb appoints Mayada Al-Ahmad, a 24-year pharma veteran, to lead its Saudi and Gulf operations, aligning with the region's ambitious health goals.

As federal support for science wanes, the National Cancer Center adds top minds from Stanford and Harvard to identify and fund the next wave of cancer cures.

Gelteq aims to replace needles with its ingestible gel, targeting diabetes and more. But can it balance this lofty goal with near-term revenue and tight finances?

Insilico Medicine's AI-designed drug, ISM8969, enters human trials, targeting chronic neuroinflammation by crossing the elusive blood-brain barrier.

Gene therapy firm uniQure plans a 2026 FDA submission for AMT-130, a potential first disease-modifying treatment for Huntington's, on an accelerated track.

ARMR Sciences reports a major breakthrough in the fight against overdose, but can a preventative vaccine truly turn the tide on the fentanyl crisis?

Adaptive Biotechnologies' sophisticated convertible note offering isn't just about capital; it's a strategic de-risking of its finances to accelerate its fight against cancer.

Milan-based WISE secured €30M to advance its stretchable neuro-implants, aiming to solve a critical dilemma in chronic pain treatment and neurotechnology.

Chinese meat processor Wing Yip regained Nasdaq compliance via a reverse split, but a closer look reveals declining profits and intense market pressure.

Assertio Holdings delists from Nasdaq after its merger with Zydus. A deep dive into the strategic calculus and the crucial decision facing its debt holders.

Biotech firm Azitra is leveraging its engineered microbe tech to tackle rare diseases and enter the $71B cosmeceutical market. Is this a brilliant pivot or a risky bet?

Opus Genetics unveils a multi-program gene therapy pipeline, backed by a robust financial runway, aiming to systematically dismantle inherited retinal diseases.

Two agricultural giants are joining forces to deploy rimisoxafen, a novel dual-action herbicide, in a decade-long deal aimed at conquering superweeds.

Health Canada issues a stark warning on illegal hyperbaric chambers in wellness centres, citing fatal risks. How did these devices bypass the path to profit?

LiberNovo's new Maxis chair isn't just furniture; it's a challenge to the flawed, one-size-fits-all systems that fail a growing part of the workforce.

As nations race to finalize a pandemic treaty, a battle over enforceable equity threatens to derail the entire process. Will it be a new era of cooperation or a repeat of past failures?

New data shows stable anxiety rates, yet over half of Canadians abandon mental health care early. What's really happening beneath the surface of our well-being?